Eureka Therapeutics Closes $60 Million in Series D Financing to Advance Proprietary ARTEMIS™ T Cell Receptor … – Business Wire (press release)
|
Eureka Therapeutics Closes $60 Million in Series D Financing to Advance Proprietary ARTEMIS™ T Cell Receptor …
Business Wire (press release) This financing represents an important validation of our strategy, and provides us the resources to advance our ARTEMIS™ T cell platform into clinical development,” said Cheng Liu, PhD, President and Chief Executive Officer of Eureka. “This financing … |
